Study: Medicare Rules Increase Out-of-Pocket Costs of MS Drugs
* * *
- Medicare beneficiaries now pay thousands of dollars annually
* * *
Medicare patients with multiple sclerosis face skyrocketing out-of-pocket costs for therapies due to complicated insurance rules that force them to pick up an increasing share of the cost, according to new research.
Despite recent efforts to constrain escalating costs, researchers with OHSU in
Medicare beneficiaries without low-income subsidies can expect to spend
"It's a dysfunctional market that lacks the typical incentives for most other consumer prices," said lead author
High prices negatively affect patients, even with insurance, because patient out-of-pocket costs are often directly tied to undiscounted drug list prices. Additionally, rising prices for MS therapies also seemed to correlate to increased use of restrictive policies by Medicare pharmacy plans.
In one telling example, researchers documented how patients who are prescribed the only generic drug in one class - glatiramer acetate - will pay more out of pocket than patients using any of the other brand-name drugs in the same class. The Bipartisan Budget Act of 2018 modified Medicare payment rules to reduce out-of-pocket costs for individuals through increased discounts provided by brand-name drug manufacturers. However, this change left individuals who use generic drugs with higher out-of-pocket costs for certain generic products.
"This is a pernicious effect of the release of a generic and an unfortunate effect of Medicare rules," said co-author
The authors noted that a proposal by the Trump administration would reduce this incentive disparity between brand-name and generic drugs. Depending on drug utilization patterns, the authors expect the administration's suggested changes would reduce total out-of-pocket spending for beneficiaries.
The study follows on previous research into the high cost of MS drugs led by Hartung and Bourdette.
"MS is emblematic of many chronic conditions whose treatment increasingly involves the use of high-cost specialty drugs that are often rigidly managed," the authors write.
Researchers also examined changes in requirements for prior authorization, a common insurance company strategy intended to manage or limit access to certain drugs. The study noted that rates of pre-authorization have increased from 61 percent in 2007 to as high as 90 percent in 2016. Yet narrowing options doesn't necessarily work for MS patients, the authors write, noting
"Despite increases in the number and diversity of disease-modifying therapies for MS, prices have risen rapidly over the past two decades," the authors write. "The rise in high coinsurance cost-sharing models, coupled with escalating drug prices, means that patients will increasingly face prohibitive out-of-pocket spending."
Trump Has Solid US Economy For SOTU, But Threats Remain
Cascade Care, Washington’s Next Step in Affordable Health Care for All, Has Public Hearing
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News